These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1179 related articles for article (PubMed ID: 14669796)

  • 1. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
    Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
    Konjević G; Jović V; Radomirović V; Spuzić I
    Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
    Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
    Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
    Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma.
    Jović V; Konjević G; Radulović S; Jelić S; Spuzić I
    Tumori; 2001; 87(5):324-9. PubMed ID: 11765182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.
    Schmittel A; Keilholz U; Max R; Thiel E; Scheibenbogen C
    Int J Cancer; 1999 Jan; 80(1):39-43. PubMed ID: 9935227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
    Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
    J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
    Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
    Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
    Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
    Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
    Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
    J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
    Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
    Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
    J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.